Navigation Links
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer
Date:11/18/2009

For cancer patients on chemotherapy, the "cure" can be as deadly as the disease itself. Adverse drug reactions are one of the leading causes of death among patients receiving cancer treatment.

Jackson Laboratory Professor Gary Churchill wants to change that. With a new two-year, $1 million grant from the National Cancer Institute, Churchill is launching a radical new approach to testing three chemotherapeutic drugs for potential toxic effects.

Chemo drugs are supposed to be toxicto cancer cells. But they're notorious for their unpredictable effectiveness and for causing systemic toxic reactions in patients.

"Adverse drug reactions can be difficult to study in humans," Churchill says. "Every individual is genetically unique and lives in an uncontrolled environment. That's why we need animal model systems to fully understand the genetic basis of drug response."

Testing chemo drugs in animal models is not new, but Churchill's approach is. Instead of working with one hybrid strain of mouse, as is the pharmaceutical industry standard, The Jackson Laboratory is developing a new mouse variety that is designed to maximize genetic diversity. Each one of these "Diversity Outbred Mice" will be genetically unique and, as a whole, the population approximates the genetic diversity observed in human populations.

To develop the Diversity Outbred Mice, Churchill is teaming up with Neal Goodwin, Ph.D., who directs cancer studies at JAXWest, The Jackson Laboratory's facility in Sacramento, Calif.

Sophisticated genetic mapping and live-animal imaging techniques will enable Churchill and Goodwin to home in on the gene variations found in mice that exhibit a toxic reaction. "So in terms of the information we're getting, it's almost like testing chemo drugs on every person on Earth," Churchill says. "This sets the scene for future, highly reliable screens for cancer patients."

The three drugs in the studydoxorubicin, cyclophosphamide, docetaxelwere chosen because of their well-known myelotoxic effects. Myelotoxicity or bone marrow suppression reduces the production of blood cells, hampering the body's ability to fight infection and causing anemia and other severe problems.

"We have chosen myelosuppression as the physiological response for this study," Churchill says, "because this adverse effect is a major contributor to morbidity, mortality and costs associated with cancer treatment. Mice are known to respond to these agents in a manner similar to humans, and the response can be measured using standard clinical hematological methods."

Imogen Hurley, Ph.D., an associate research scientist in Churchill's laboratory, notes that the approach behind these experiments will be relevant to all types of drugs. "Cancer drugs are an important test case. We expect to show that researchers will be able to use the genetic diversity of these mice to understand why individuals have different reactions to a wide range of drugs."


'/>"/>

Contact: Joyce Peterson
joyce.peterson@jax.org
207-288-6058
Jackson Laboratory
Source:Eurekalert

Related biology news :

1. Avocados may help prevent oral cancer, OSU study shows
2. St. Jude identifies the specific cell that causes eye cancer, disproving long-held theory
3. Chemical in red wine, fruits and vegetables stops cancer, heart disease, depending on the dose
4. Exposure to low levels of radon appears to reduce the risk of lung cancer, new study finds
5. T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
6. Fruits, vegetables and teas may protect smokers from lung cancer, UCLA researchers report
7. Control switches found for immune cells that fight cancer, viral infection
8. Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds
9. Landmark study opens door to new cancer, aging treatments
10. In lung cancer, silencing one crucial gene disrupts normal functioning of genome
11. UT Southwestern researchers disrupt biochemical system involved in cancer, degenerative disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 2016  The American College of Medical Genetics and Genomics ... as one of the fastest-growing trade shows during the ... Bellagio in Las Vegas . ... growth in each of the following categories: net square feet ... of attendees. The 2015 ACMG Annual Meeting was ranked 23 ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/15/2016)... 2016 Transparency Market Research ... Market by Application Market - Global Industry Analysis Size Share ... the report, the  global gesture recognition market  was ... is estimated to grow at a CAGR of ... Increasing application of gesture recognition technology ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
Breaking Biology Technology: